ScreenPoint Medical's Transpara AI Chosen for $16M Breast Cancer Screening Trial

ScreenPoint Medical has announced that its Transpara breast imaging AI solution will be used in the PRISM Trial, a significant randomized controlled trial in the United States. Announced in a press release, the trial is funded by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI) and aims to assess the effectiveness of AI in breast cancer screening.

The PRISM Trial, led by UCLA and UC Davis, will explore whether AI can assist radiologists in detecting breast cancer earlier, improving mammography accuracy, and reducing unnecessary patient callbacks. The study will involve hundreds of thousands of mammograms interpreted at leading academic medical centers, including UCLA, UC Davis, and others.

ScreenPoint Medical's Transpara Detection software will be integrated into the clinical workflow using the Aidoc aiOS platform, supporting the trial's objectives to enhance early breast cancer detection and improve patient-centered care systems.